Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Basil Elnazir

Professor

Trinity College Dublin

Ireland

Research Interests

Explore related searches

Professors in Ireland

Articles (20)

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (3)

Laura Kirwan

Head of Research

University College Dublin

IRELAND

View details

Jochen G. Mainz

GERMANY

View details

Paul McNally

Associate Professor

Royal College of Surgeons in Ireland

IRELAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Basil Elnazir

Research Interests

Explore related searches

Articles (20)

The need to restudy SABA regimens on discharge of children with an acute asthma exacerbation: A scoping review

Case Reflection of a Child With p.Phe312del/p.Phe508del Genotype Undetected on Newborn Screening and With No Clinical Features of Cystic Fibrosis Despite a Sweat Chloride Value in the Diagnostic Range

Global Pediatric Pulmonology Alliance recommendations to protect all infants against respiratory syncytial virus with prophylactic monoclonal antibodies

WS10.02Proteomic analysis of nasal lavage fluid and sputum samples in people with cystic fibrosis during 24 months of treatment with elexecaftor/tezacaftor/ivacaftor - The RECOVER study

A Unique Mutation in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene Causing Cystic Fibrosis in a Pakistani Child: A Case Highlighting the Need for More Awareness

Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged ≥12 years – The RECOVER study

Improvement in Lung Clearance Index and Chest Computed Tomography Scores with Elexacaftor/Tezacaftor/Ivacaftor Treatment in People with Cystic Fibrosis Aged 12 Years and Older – The RECOVER Trial

138 Clinical outcomes in people with cystic fibrosis after 2 years of elexacaftor-tezacaftor-ivacaftor: Results from the RECOVER study

142 Elexacaftor-tezacaftor-ivacaftor and spirometry-controlled chest CT scores in children with cystic fibrosis aged 6 to 11

144 Changes in airway nitric oxide in people with cystic fibrosis taking elexacaftor-tezacaftor-ivacaftor—Results from the RECOVER study

196 Airway infection and inflammation in people with cystic fibrosis treated with 1 year of elexacaftor-tezacaftor-ivacaftor—the RECOVER study

485 Measuring adherence to chronic therapies over 2 years of treatment with elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis—the RECOVER Study

626 Timing of Pseudomonas aeruginosa acquisition in children diagnosed with cystic fibrosis recruited in the Irish Comparative Outcome Study Part 2

The clinical impact of Lumacaftor-Ivacaftor on structural lung disease and lung function in children aged 6–11 with cystic fibrosis in a real-world setting

EPS2.05 The challenge of living with cystic fibrosis - short form - challenges experienced by parents/caregivers of children with Cystic Fibrosis in Ireland: the Irish Comparative Outcomes study (ICOS)

EPS6.02 Elexacaftor/tezacaftor/ivacaftor results in substantial improvements in chest CT scores in people with cystic fibrosis aged 12 and above over one year of treatment

EPS6.06 Impact of 6 months of treatment with elexacaftor/tezacaftor/ivacaftor on clinical outcomes in children aged 6–11 with cystic fibrosis – The RECOVER study

EPS6.07 Longitudinal impact of elexacaftor/tezacaftor/ivacaftor on abdominal symptoms assessed with the CFAbd-Score and on intestinal inflammation in people with cystic fibrosis aged ≥ 12 years – The RECOVER study

EPS7.06 Hospital admissions due to pulmonary exacerbation in the first five years of life in children with cystic fibrosis in Ireland: the Irish Comparative Outcome Study of cystic fibrosis (ICOS)

P038 Direct measurement of short-term adherence to elexacaftor/tezacaftor/ivacaftor and changes in sweat chloride levels – results from the RECOVER Study

Collaborators (3)

Laura Kirwan

Jochen G. Mainz

Paul McNally

Make your next move.